Simonian Nancy A
SEC insider (Form 3/4/5 filer). CIK 0001359574. Director at Generate Biomedicines, Inc. (GENB) and 1 other issuer. 4 reported Form 4/5 transactions since Sep 2024; latest on Feb 26, 2026. Located in SOMERVILLE, MA.
Companies Simonian Nancy A has filed insider reports for
- Generate Biomedicines, Inc. (GENB): Director
- Syros Pharmaceuticals, Inc. (SYRS): Director
Simonian Nancy A
CIK: 0001359574
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)2 (50.0%)
Position reduction
Option Exercises (M)1 (25.0%)
Derivative conversions
Awards (A)1 (25.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Feb 26, 2026GENB
Generate Biomedicines, Inc.
AwardDirectStock Option (Right to Buy)
29.6K shares- - Dec 2, 2024SYRS
Syros Pharmaceuticals, Inc.
SaleDirect37.1K shares at avg. $0.27$10K - Nov 25, 2024SYRS
Syros Pharmaceuticals, Inc.
SaleDirect134.7K shares at avg. $0.27$36K - Oct 31, 2024SYRS
Syros Pharmaceuticals, Inc.
ExerciseDirect40.1K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Feb 26, 2026 |  GENB Generate Biomedicines, Inc. | Award Stock Option (Right to Buy) | 29,561 | - | - | Direct |
| Dec 2, 2024 |  SYRS Syros Pharmaceuticals, Inc. | Sale | 37,070 | $0.27 | $10,016 | Direct |
| Nov 25, 2024 | SYRS Syros Pharmaceuticals, Inc. | Sale | 134,713 | $0.27 | $35,739 | Direct |
| Oct 31, 2024 | SYRS Syros Pharmaceuticals, Inc. | Exercise | 40,125 | - | $0 | Direct |
1-4 of 4 transactions